UBS Group’s Rain Oncology Inc. Common Stock RAIN Stock Holding History

UBS Group’s Portfolio RAIN Stock Details RAIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-29,291	Closed	-$35.1K	–	10409
2023 Q4	$35.1K	Buy	29,291 +20,644	+239%	+$22.3K	﹤0.01%	6752
2023 Q3	$7.45K	Sell	8,647 -1,264	-13%	-$1.39K	﹤0.01%	7232
2023 Q2	$11.9K	Buy	9,911 +8,071	+439%	+$40.4K	﹤0.01%	7090
2023 Q1	$16.1K	Buy	1,840 +927	+102%	+$8.57K	﹤0.01%	7251
2022 Q4	$7.3K	Sell	913 -785	-46%	-$4.93K	﹤0.01%	8912
2022 Q3	$8K	Buy	+1,698	New	+$10.7K	﹤0.01%	8781
2022 Q2	–	Sell	-692	Closed	-$4K	–	11261
2022 Q1	$4K	Sell	692 -5,223	-88%	-$41.9K	﹤0.01%	9358
2021 Q4	$76K	Buy	+5,915	New	+$84.5K	﹤0.01%	6544

UBS Group's RAIN Position: Q1 2024 in Review

UBS Group sold out of Rain Oncology Inc. Common Stock (RAIN) in Q1 2024, closing a stake of 29,291 shares — an estimated $35.1K sold.

UBS Group first reported a position in RAIN in Q4 2021 and held it in 8 quarters. The position peaked at $76K in Q4 2021. 0 funds tracked by Wall St. Rank hold RAIN as of Q1 2024.

UBS Group reported no remaining Rain Oncology Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
UBS Group sold 29,291 Rain Oncology Inc. Common Stock shares in Q1 2024, an estimated $35.1K.
UBS Group first reported a position in Rain Oncology Inc. Common Stock in Q4 2021 and held it in 8 quarters.
UBS Group's Rain Oncology Inc. Common Stock position peaked at $76K in Q4 2021.
0 funds tracked by Wall St. Rank held Rain Oncology Inc. Common Stock as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.